DT/VSB/26 (07.00)

Approved for use literage 2017 POSSES 60.700 POSSES 60.700

REJECTION OVER A "F		101961-5126-US (7946.204-US)
In re Application of Shawn DeFrees		
Application No.: 10/549,528		
Filed: September 19, 2005		
For: INTRACELLULAR FORMATION OF PEPTIDE CO.	NJUGATES	
The owner*, Novo Nordisk A/S except as provided below, the terminal part of the stable the expiration date of the full statutory term prior patent and 173, and as the term of said prior patent is presenganted on the instant application shall be enforceable agreement runs with any patent granted on the instant application.	tory term of any patent granted on the inst it No. 7,179,617 as the term of only shortness day any terminal disclaimer, only for and duting such period that it and application and is binding upon the grantee	f said prior patent is defined in 35 U.S.C. 154. The owner hereby agrees that any patent so the prior patent are commonly owned. This it, its successors or assigns.
In making the above discisimer, the owner does not disk would extend to the expiration date of the full statutory to patent is presently shortened by any terminal disclaimer expires for failure to pay a maintenance fee, is held unenforceable; is found invalid by a court of competent jurisdiction, is a statutorily disclaimed in whole or terminally discla- nas all claims canceled by a reexamination certifice is relisated, or exeramination certifice is in any mismorr terminated prior to the expiration of the properties of the properties of the control of the service of in any mismorr terminated prior to the expiration of the control of the properties of the properties of the control of the termination of the properties of the properties of the termination of the termination of the termination of the termination of the termination of the termination of the termination of termination o	erm as defined in 35 U.S.C. 154 and 173 (r, in the event that said prior patent later. : aimed under 37 CFR 1.321; ste.	of the prior patent, "as the term of said prior :
Check either box 1 or 2 below, if appropriate.		
For submissions on behalf of a business/organiet.), the undersigned is empowered to act on the organization of the organi	behalf of the business/organization. ein of my own knowledge are true and that atements were made with the knowledge under Seiction 1001 of Title 18 of the Unit	hat all statements made on in formation and
2. The undersigned is an attorney or agent of rec		(3/2 /3) Oate
	Len S. Smith, Esq., Senior Counsel, Reg.	No. 43,139
	Typed or printed name	
		(609) 987-5800
		Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d)) included.	
WARNING: Information on this f be included on this form. Provid	form may become public. Credit card in the credit card information and authoriza	formation should not ation on PTO-2038.
*Statement under 37 CFR 3,73(b) is required if terminal	disclaimer is signed by the assignee (owr	ner).

This collection of information is required by 37 CFR 1.321. The information is prequired to obtain or retain a benefit by the public vehich is to file (and by the USPTO to process) an application. Confidentiably is governed by 25 U.S.C. 172 and 37 CFR 1.11 and 1.14. This collection is estimated to late 17 influents to complete to complete the confidence of the confidenc